$ZVRA Reports Q4 2025 Revenue Growth Amidst Pipeline Advancements

Zevra Therapeutics, Inc. (ZVRA) reported its financial results for the fourth quarter and full year ended December 31, 2025, highlighting significant revenue growth and continued progress in its rare disease pipeline. The company posted **net product revenue of $15.2 million** for Q4 2025, primarily driven by robust sales of its attention-deficit/hyperactivity disorder (ADHD) treatment, **AZSTARYS®**.

Key Takeaways

• Zevra Therapeutics recorded **Q4 2025 net product revenue** of **$15.2 million**, largely attributable to increasing demand for **AZSTARYS®**, according to the Q4 2025 Earnings Call Transcript.
• The company maintained a strong liquidity position, ending **December 31, 2025**, with **$120 million** in cash and cash equivalents, per the Q4 2025 Earnings Call Transcript.
• Clinical development for **KP1077**, Zevra’s lead product candidate for narcolepsy and idiopathic hypersomnia, remains on schedule with Phase 3 trials progressing as planned, as stated in the Q4 2025 Earnings Call Transcript.
• Management provided **FY 2026 revenue guidance** projecting between **$70 million and $80 million**, reflecting anticipated growth in product sales and pipeline milestones, according to the Q4 2025 Earnings Call Transcript.

The **Q4 2025 results** underscore Zevra’s dual strategy of commercializing **AZSTARYS®** while advancing its specialized rare disease pipeline. The **$15.2 million in net product revenue** for the quarter represents a significant increase, although specific comparative figures were not detailed in the transcript summary.

Further strengthening its financial foundation, **Zevra** reported a healthy cash balance of **$120 million** at year-end. This capital is crucial for funding ongoing research and development efforts, particularly for its promising rare disease assets.

A key focus during the earnings call was the clinical progression of **KP1077**. The program, targeting debilitating conditions like narcolepsy and idiopathic hypersomnia, is currently in Phase 3 development, a critical stage that could unlock substantial market opportunities for Zevra.

Looking ahead, the company issued **FY 2026 revenue guidance** in the range of **$70 million to $80 million**. This outlook is predicated on continued momentum from **AZSTARYS®** sales and potential advancements or milestones within its rare disease portfolio.

Market Insight

Analysts note that **Zevra’s** performance in **Q4 2025** highlights the delicate balance for specialty pharmaceutical companies between commercial execution and pipeline development. The strong **AZSTARYS®** sales provide a critical revenue stream, potentially reducing reliance on dilutive financing rounds, which is often a significant concern for smaller biotechs. However, the long-term valuation remains heavily tied to the success of its rare disease candidates, particularly **KP1077**.

The projected **FY 2026 revenue guidance** suggests confidence in both continued product growth and the strategic direction. Key risks include the highly competitive landscape for ADHD treatments, where **AZSTARYS®** must continue to differentiate itself, and the inherent clinical and regulatory risks associated with late-stage drug development for **KP1077**. A positive outcome for **KP1077’s Phase 3 trials** could be a transformative catalyst, while any setbacks could lead to significant share price volatility.